NCT05561309

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management

A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management compared with ropivacaine.

Conditions

• Total Knee Arthroplasty

Interventions

Type	Name	Description
DRUG	HR18034;Ropivacaine Hydrochloride Injection	Drug: HR18034 Drug: Ropivacaine Hydrochloride Injection Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management. Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution

Timeline

• Start date: 2022-10-20
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2022-09-30
• Last updated: 2024-03-04

Locations

1 site across 1 country: China